<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.118496</article-id><article-id pub-id-type="publisher-id">ACM-44431</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210800000_37150936.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  新型免疫检查点在宫颈癌中的应用前景
  Application Prospects for New Immune Checkpoints in Cervical Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>玉英</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>丽</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>袁</surname><given-names>芳</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青岛大学附属医院，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff2"><addr-line>青岛大学，山东 青岛</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>08</month><year>2021</year></pub-date><volume>11</volume><issue>08</issue><fpage>3418</fpage><lpage>3425</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  宫颈癌是我国常见的妇科恶性肿瘤之一，对于中晚期及复发转移性宫颈癌患者的治疗仍面临诸多挑战，肿瘤免疫疗法取得突破性进展，这主要归于免疫检查点的发现，目前针对CTLA-4和PD-1的免疫疗法己经成功应用于几种恶性肿瘤的治疗，并取得了切实的治疗效果。本文将简要综述免疫检查点在宫颈癌中的作用机制，并简要综述TIM-3、TIGIT、LAG-3和VISTA等新型免疫检查点在恶性肿瘤中的表达及临床意义。
   Cervical cancer is one of the common gynecological malignant tumors in my country. For the treatment of patients with mid-term and recurrent metastatic cervical cancer, the treatment of tumor immunotherapy has made breakthrough progress, which is mainly due to the discovery of immune checkpoint, currently targeting the immunotherapy of CTLA-4 and PD-1 has been successfully applied to several malignant tumors, and has achieved practical treatment. This paper briefly reviews the mechanism of action in cervical cancer, and briefly reviews the expression of TIM-3, TIGIT, LAGIT, LAG-3 and Vista in malignant tumor and clinical significance.
 
</p></abstract><kwd-group><kwd>宫颈癌，免疫检查点，肿瘤微环境，免疫治疗, Cervical Cancer</kwd><kwd> Immune Checkpoint</kwd><kwd> Tumor Microenvironment</kwd><kwd> Immunotherapy</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>宫颈癌是我国常见的妇科恶性肿瘤之一，对于中晚期及复发转移性宫颈癌患者的治疗仍面临诸多挑战，肿瘤免疫疗法取得突破性进展，这主要归于免疫检查点的发现，目前针对CTLA-4和PD-1的免疫疗法己经成功应用于几种恶性肿瘤的治疗，并取得了切实的治疗效果。本文将简要综述免疫检查点在宫颈癌中的作用机制，并简要综述TIM-3、TIGIT、LAG-3和VISTA等新型免疫检查点在恶性肿瘤中的表达及临床意义。</p></sec><sec id="s2"><title>关键词</title><p>宫颈癌，免疫检查点，肿瘤微环境，免疫治疗</p></sec><sec id="s3"><title>Application Prospects for New Immune Checkpoints in Cervical Cancer<sup> </sup></title><p>Yuying Li<sup>1</sup>, Li Zhao<sup>1</sup>, Fang Yuan<sup>2</sup></p><p><sup>1</sup>Qingdao University, Qingdao Shandong</p><p><sup>2</sup>The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/13-1572427x4_hanspub.png?20210809171614386" /></p><p>Received: Jul. 4<sup>th</sup>, 2021; accepted: Aug. 2<sup>nd</sup>, 2021; published: Aug. 9<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/13-1572427x5_hanspub.png?20210809171614386" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Cervical cancer is one of the common gynecological malignant tumors in my country. For the treatment of patients with mid-term and recurrent metastatic cervical cancer, the treatment of tumor immunotherapy has made breakthrough progress, which is mainly due to the discovery of immune checkpoint, currently targeting the immunotherapy of CTLA-4 and PD-1 has been successfully applied to several malignant tumors, and has achieved practical treatment. This paper briefly reviews the mechanism of action in cervical cancer, and briefly reviews the expression of TIM-3, TIGIT, LAGIT, LAG-3 and Vista in malignant tumor and clinical significance.</p><p>Keywords:Cervical Cancer, Immune Checkpoint, Tumor Microenvironment, Immunotherapy</p><disp-formula id="hanspub.44431-formula35"><graphic xlink:href="//html.hanspub.org/file/13-1572427x6_hanspub.png?20210809171614386"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/13-1572427x7_hanspub.png?20210809171614386" /> <img src="//html.hanspub.org/file/13-1572427x8_hanspub.png?20210809171614386" /></p></sec><sec id="s5"><title>1. 引言</title><p>宫颈癌是女性生殖系统常见的恶性肿瘤，发病率及死亡率在女性恶性肿瘤中位居第四位，据2020年世界癌症统计数据显示，全球病例超过60.4万例，死亡34.2万人。宫颈癌在发展中国家的发病率和死亡率远高于发展中国家，全球约85%的宫颈癌患者发生在发展中国家，约占所有女性癌症的12% [<xref ref-type="bibr" rid="hanspub.44431-ref1">1</xref>]。而我国宫颈癌每年的新发病例大约在13.15万人左右，因其死亡的人数每年约有5.3万，占全部女性恶性肿瘤死亡人数的18.4%左右 [<xref ref-type="bibr" rid="hanspub.44431-ref2">2</xref>]。因此可见宫颈癌是严重威胁妇女健康的一种疾病，也是最常见的恶性肿瘤之一。在过去几年中，肿瘤免疫疗法取得突破性进展，CTLA-4和PD-1的免疫疗法己经成功应用于几种恶性肿瘤的治疗，并取得了切实的治疗效果 [<xref ref-type="bibr" rid="hanspub.44431-ref3">3</xref>]。然而许多免疫检查点抑制剂存在机体耐药性等治疗缺陷，因此研究新型免疫检查点对于复发、转移宫颈癌患者具有重要意义，本文将简要概述TIM-3、TIGIT、LAG-3和VISTA [<xref ref-type="bibr" rid="hanspub.44431-ref4">4</xref>] 这四种免疫检查点分子在宫颈癌中作用，并对宫颈癌未来免疫治疗提出展望。</p></sec><sec id="s6"><title>2. 肿瘤的免疫逃逸机制</title><sec id="s6_1"><title>2.1. 机体正常的免疫监视</title><p>在正常生理状态下，机体免疫系统具有识别“自己”抗原和“异己”抗原的能力，在识别了“异己”抗原后，免疫系统将会被激活并杀伤“异己”。在肿瘤产生之初，肿瘤细胞会释放特异性的肿瘤相关抗原，树突状细胞等抗原递呈细胞(antigen presenting cells, APCs)识别摄取并加工肿瘤抗原，ACPs进入淋巴组织激活T细胞，T细胞被激活后迁移至肿瘤部位，渗透至肿瘤组织，T细胞通过特异性的受体识别并杀死肿瘤细胞，而肿瘤细胞凋亡后又会表达和释放更多的肿瘤相关抗原，进一步激活更多的T细胞以维持机体有效的免疫监视，避免机体内肿瘤的发生 [<xref ref-type="bibr" rid="hanspub.44431-ref5">5</xref>]。</p></sec><sec id="s6_2"><title>2.2. 肿瘤的免疫逃逸机制和相应的治疗策略</title><p>正常情况下，肿瘤的发生发展过程中必然会累积众多突变，这些不同的突变会编码众多“异己”抗原，使得产生突变的肿瘤细胞被免疫系统识别并清除。但是，肿瘤细胞在与免疫系统的抗争过程中，可以获得多种逃脱免疫系统监视的方法，最终导致肿瘤的发生。肿瘤的免疫逃逸机制，大致可分为以下三个方面 [<xref ref-type="bibr" rid="hanspub.44431-ref6">6</xref>]：① 免疫原性丧失：肿瘤细胞虽能表达某些特殊抗原，可以被免疫系统识别，但是这些肿瘤细胞可以通过其他一些分子(如免疫检查点)的表达，即通过免疫检查点的配体受体结合抑制活化的T淋巴细胞从而起到抑制免疫系统的作用，也是造成免疫逃逸的关键原因 [<xref ref-type="bibr" rid="hanspub.44431-ref7">7</xref>]。在这种情况下，虽然免疫系统可以识别肿瘤细胞，却不能被有效激活，不能发挥杀死肿瘤细胞的作用。因此，针对肿瘤细胞免疫原性的丧失，研究者开始尝试阻断免疫检查点的配体受体结合进而激活免疫细胞以达到抗肿瘤的目的 [<xref ref-type="bibr" rid="hanspub.44431-ref8">8</xref>]，以PD-1/PD-L1单抗为代表的ICIs疗法已经改变了肿瘤治疗的格局。ICIs能够抑制T细胞表面的PD-1与肿瘤细胞表面的PD-L1配体结合，再次激活T细胞，发挥杀死肿瘤细胞的作用。② 抗原性丧失：肿瘤细胞通过丧失特殊抗原的表达来避开免疫系统的识别，从而躲避免疫系统的杀伤。针对肿瘤细胞表面抗原的丧失，具有代表性的免疫疗法是嵌合抗原受体T细胞(chimeric antigen receptor T-cell, CAR-T)治疗，即通过细胞工程技术改造免疫细胞，使之可以识别肿瘤细胞表面的其他特定“异己”抗原而杀死肿瘤细胞。CAR-T治疗已在血液肿瘤领域取得了重大进展 [<xref ref-type="bibr" rid="hanspub.44431-ref9">9</xref>]，但在实体瘤领域，CAR-T治疗尚未取得实质性进展。③ 免疫抑制微环境：虽然在实体肿瘤组织中浸润的免疫细胞在体外环境下仍能发挥有效作用，但在实体肿瘤组织内，存在多种负性调节的细胞和细胞因子，共同构成了肿瘤组织周围的免疫抑制的微环境，阻止免疫系统发挥正常的杀死肿瘤细胞的作用。针对免疫抑制微环境，可通过干扰肿瘤微环境中存在的多种抑制免疫反应的细胞因子来实现肿瘤免疫治疗的目的。如利用间变性淋巴瘤激酶5 (anaplastic lymphoma kinase, ALK-5)抑制剂抑制肿瘤转移 [<xref ref-type="bibr" rid="hanspub.44431-ref10">10</xref>]，目前尚处于临床研究阶段。</p></sec></sec><sec id="s7"><title>3. 肿瘤的免疫治疗</title><sec id="s7_1"><title>3.1. 肿瘤治疗新进展</title><p>传统的抗肿瘤治疗包括手术、放疗、化疗，但是治疗效果非常有限，且副作用明显，对患者生存质量有极大的影响。近年来肿瘤的免疫治疗成为众多学者研究的热点领域，并在2013年被《科学》杂志评为十大科技突破首位 [<xref ref-type="bibr" rid="hanspub.44431-ref11">11</xref>]，免疫负调控治疗肿瘤的研究成果被授予2018年诺贝尔生理学或医学奖 [<xref ref-type="bibr" rid="hanspub.44431-ref12">12</xref>]，将肿瘤免疫治疗的作用推向新的高度。</p></sec><sec id="s7_2"><title>3.2. 肿瘤免疫治疗</title><p>肿瘤免疫疗法是一类通过激活患者自身的免疫系统来治疗癌症的方法，是继手术、放疗、化疗之后抗肿瘤治疗的第四大领域。肿瘤免疫疗法发展迅速，第一代为缺乏靶向性细胞的淋巴因子激活的杀伤细胞(NK细胞)、细胞因子激活的杀伤细胞(CIK细胞)治疗；第二代为通过同时输入树突状细胞(DC细胞)赋予CIK细胞一定靶向性的DC-CIK治疗；第三代为利用基因编辑给T细胞加入能识别肿瘤细胞并激活T细胞杀死肿瘤细胞的嵌合抗体(CAR-T疗法)；但是一直以来，关于肿瘤免疫治疗的研究主要集中在增强免疫机制上，但“免疫增强化”策略通常无法达到客观缓解，并有频繁的免疫相关不良事件(immune-related-Adverse evens, ir AEs)发生。至此，第四代免疫检查点抑制剂和肿瘤疫苗技术应运而生，比如针对程序性死亡受体–配体1 (programmed cell death-ligand1, PD-L1, B7-H1)/程序性死亡受体1 (programmed cell death protein 1, PD-1)途径的肿瘤免疫疗法在患者中取得了更高的客观缓解，且ir AEs少得多，其原因是作用机制的不同，此机制是选择性地恢复肿瘤微环境中由肿瘤引起的免疫缺陷，这里称为“免疫正常化(immune normalization)”，此概念由美国耶鲁大学陈列平教授首次提出 [<xref ref-type="bibr" rid="hanspub.44431-ref13">13</xref>]。“免疫正常化”主要根据肿瘤免疫逃逸机制，靶向肿瘤微环境，治疗效果更加有效且毒性更低。免疫正常化策略可围绕以下几个方面展开：瞄准肿瘤诱导的免疫逃逸机制，选择性调整肿瘤免疫微环境中的应答，重塑肿瘤微环境中的免疫能力。免疫检查点抑制剂因其显著的疗效成为明星热点 [<xref ref-type="bibr" rid="hanspub.44431-ref14">14</xref>]，免疫检查点的相关研究也到达了一个新的高度。</p></sec><sec id="s7_3"><title>3.3. 免疫检查点及其抑制剂</title><p>免疫系统可以区分一系列刺激，允许一些刺激激发免疫反应，从而导致免疫，并阻止其他刺激这样做，从而导致耐受。为此，免疫系统在不同层次(分子、细胞和系统)高度组织和协调。免疫检查点是人类免疫系统控制免疫反应的关键环节，免疫检查点包括刺激性检查点和抑制性检查点。与促进机体免疫反应的刺激性检查点不同，抑制性检查点是防止人体过激免疫反应的保护性位点，可降低自身免疫反应。在正常机体环境中，免疫检查点可对免疫应答的强度和持续性进行调节，防止在清除异常细胞过程中损伤正常组织，在机体免疫系统中主要发挥保护作用，通过调节免疫反应的强度和广度，发挥类似于刹车作用，有效控制T细胞过度活化，在维持机体自身免疫耐受等方面发挥重要作用 [<xref ref-type="bibr" rid="hanspub.44431-ref15">15</xref>]。</p><p>在肿瘤微环境中，肿瘤细胞常过度表达免疫检查点信号，抑制机体免疫系统及其效应因子作用，免疫检查点通路被利用，抑制性信号被进一步放大，T细胞功能受到抑制，导致肿瘤免疫逃逸 [<xref ref-type="bibr" rid="hanspub.44431-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.44431-ref17">17</xref>]。在恶性肿瘤中，CTLA-4主要通过与CD-28竞争性结合CD-80和CD-86，从而抑制CD-28将活化信号传递给T细胞，使T细胞不能彻底活化；而PD-1则能调节发生免疫反应的组织中的效应T细胞活性，使其不能发挥作用，二者通过不同的机制抑制免疫反应，从而帮助肿瘤细胞免疫逃逸。</p><p>免疫检查点抑制剂通过阻断抑制性检查点与相关配体间的相互作用，阻断对T细胞的抑制信号，调节机体免疫细胞活性，即重新活化T细胞的功能，进而发挥抗肿瘤作用。基于这一原理，采用共抑制分子(或配体)的单隆抗体来阻断其信号，可以重新激活T细胞活性，细胞毒性T淋巴细胞相关蛋白4 (cytotoxic T lymphocyte-associated antigen-4, CTLA-4)和PD-L1 (B7-H1)/PD-1是目前临床上此类单抗最常用的靶分子，并在恶性黑色素瘤等类型肿瘤的临床治疗中显示令人振奋的结果 [<xref ref-type="bibr" rid="hanspub.44431-ref18">18</xref>]。其中在2011年，CTLA-4 单抗Ipilimumab已被FDA批准用于治疗晚期黑色素瘤；在2014年，PD-1单抗Nivolumab (欧狄沃)和Pembrolizumab (齐内达)被FDA批准用于治疗非小细胞肺癌和黑色素瘤。同时，以上3种单抗用于头颈癌、肾细胞癌、卵巢癌、膀胱癌、尿路上皮癌以及小细胞肺癌治疗的临床试验正在进行中。除此之外，CTLA-4单抗Tremelimumab、PD-1单抗Pidilizumab、B7-H1单抗MPDL3280A以及BMS936559等均处于不同阶段的临床试验中。针对其他共抑制分子如OX40、4-1BB的单抗也在研发之中 [<xref ref-type="bibr" rid="hanspub.44431-ref19">19</xref>]。</p></sec></sec><sec id="s8"><title>4. 新兴免疫检查点</title><p>新近研究发现，T细胞包含抗病毒及抗肿瘤功能，多种免疫抑制受体参与T细胞免疫调控 [<xref ref-type="bibr" rid="hanspub.44431-ref20">20</xref>]。如T 细胞免疫球蛋白黏蛋白分子3 (T cell immunoglobulin mucin 3, TIM3) [<xref ref-type="bibr" rid="hanspub.44431-ref21">21</xref>]、T细胞免疫球蛋白和免疫受体酪氨酸基抑制模体(TIGIT)、淋巴细胞活化基因-3 (lymphocyte activation gene-3, LAG3)、T细胞活化的V域免疫球蛋白抑制剂(V-domain Ig suppressor of T-cell activation, VISTA)、PD-1和CTLA-4等，抑制免疫检测点功能，可提高T细胞抗肿瘤作用，因而免疫抑制剂占有越来越重要的地位。PARRA等 [<xref ref-type="bibr" rid="hanspub.44431-ref22">22</xref>] 研究LAG3在肺癌中高情况。TIM-3证实高表达于前列腺癌细胞 [<xref ref-type="bibr" rid="hanspub.44431-ref23">23</xref>]、肝癌细胞 [<xref ref-type="bibr" rid="hanspub.44431-ref24">24</xref>]。迄今为止，在人类实体肿瘤来源的细胞中分析了TIM-3、TIGIT、LAG-3和VISTA等共抑制分子 [<xref ref-type="bibr" rid="hanspub.44431-ref25">25</xref>]，在宫颈癌的表达情况的研究罕见。</p><sec id="s8_1"><title>4.1. TIM-3</title><p>免疫检查点是肿瘤免疫中的作用关键，其自20世纪90年代被陆续发现以来在基础研究及临床应用中都取得了较多成果，2001年，MCLNTIRE等 [<xref ref-type="bibr" rid="hanspub.44431-ref26">26</xref>] 在定位克隆小鼠哮喘易感基因T细胞和气道表型调节因子(T cell and airway phenotype regulator, Tapr)时发现了T细胞免疫球蛋白黏蛋白(T-cell immunoglobulin mucin, TIM)，TIM-3即是其中一种。它选择性表达于分泌IFN-γ的CD4+、CD8+T细胞 [<xref ref-type="bibr" rid="hanspub.44431-ref27">27</xref>]，在一些肿瘤患者中它主要表达于瘤体内T细胞表面 [<xref ref-type="bibr" rid="hanspub.44431-ref28">28</xref>]。近年来，Tim-3对免疫系统的调节作用备受关注 [<xref ref-type="bibr" rid="hanspub.44431-ref29">29</xref>]。正常生理状态下，Tim-3等免疫负调控分子表达处于较低水平。一旦机体遭受慢性感染或肿瘤细胞的持续侵袭时，T细胞上的Tim-3持续性高表达并出现免疫耗竭的状态。基因敲除和荷瘤小鼠抗体治疗实验 [<xref ref-type="bibr" rid="hanspub.44431-ref30">30</xref>] 都表明，比起抗CTLA-4及抗PD-1抗体，TIM-3抗体没有引起明显的自身免疫毒副作用，提示其有较好的临床应用前景。</p></sec><sec id="s8_2"><title>4.2. TIGIT</title><p>T细胞免疫球蛋白和免疫受体酪氨酸基抑制模体(T-cell immunoglobulin and ITIM domain, TIGIT)是表达于T细胞表面的一种抑制性受体，属于免疫球蛋白超家族的一个子集，TIGIT可诱导性表达于CD4+T细胞、CD8+T细胞及NK细胞上 [<xref ref-type="bibr" rid="hanspub.44431-ref31">31</xref>] [<xref ref-type="bibr" rid="hanspub.44431-ref32">32</xref>] [<xref ref-type="bibr" rid="hanspub.44431-ref33">33</xref>]，通过与其配体的结合，抑制肿瘤的免疫反应 [<xref ref-type="bibr" rid="hanspub.44431-ref34">34</xref>]。在一项临床前小鼠模型的研究中发现，抗TIGIT单药已显示出独立的活性 [<xref ref-type="bibr" rid="hanspub.44431-ref35">35</xref>] [<xref ref-type="bibr" rid="hanspub.44431-ref36">36</xref>]。TIGIT在胃癌、结肠癌中高表达，Blessin [<xref ref-type="bibr" rid="hanspub.44431-ref37">37</xref>] 等通过分析1700例癌症患者，其中包含了86种不同实体肿瘤，该研究发现TIGIT在所研究的肿瘤中均有表达，然而在不同的瘤种之间阳性表达有所不同，在霍奇金淋巴瘤、精原细胞瘤、髓样乳腺癌、肠型胃癌及各种来源的鳞状细胞癌等淋巴细胞数量密集的肿瘤中表达较高。因此这些高表达TIGIT的肿瘤，可能会成在未来的抗TIGIT的免疫治疗中获益。总之，这些数据证明了，TIGIT是慢性抗病毒和抗肿瘤反应关键的免疫检查点抑制剂，可能代表未来免疫治疗的目标。</p></sec><sec id="s8_3"><title>4.3. LAG-3</title><p>淋巴细胞活化基因-3 (Lymphocyte Activation Gene-3, LAG-3)作为一种免疫检查点，由Triebel等 [<xref ref-type="bibr" rid="hanspub.44431-ref38">38</xref>] 在1990年首次发现报道。LAG-3主要表达于活化的CD4+T细胞、CD8+T细胞和NK细胞 [<xref ref-type="bibr" rid="hanspub.44431-ref39">39</xref>]。LAG-3又称为CD223，作为一种重要的免疫检查点，其主要在活化的CD4+和CD8+效应T细胞、B细胞和NK细胞中表达 [<xref ref-type="bibr" rid="hanspub.44431-ref40">40</xref>]。LAG-3与CD4基因位于同一区域，且两个分子之间有一定的同源性(&lt;20%) [<xref ref-type="bibr" rid="hanspub.44431-ref41">41</xref>]。有研究认为LAG-3具有抗肿瘤作用 [<xref ref-type="bibr" rid="hanspub.44431-ref42">42</xref>]，然而大多数的研究认为 [<xref ref-type="bibr" rid="hanspub.44431-ref43">43</xref>]，LAG-3通过免疫抑制微环境，抑制TIL 免疫功能介导肿瘤细胞免疫逃逸，促使肿瘤细胞发生发展和侵袭转移。已有研究报道 [<xref ref-type="bibr" rid="hanspub.44431-ref44">44</xref>]，LAG-3在多种实体恶性肿瘤中高表达。Burugu等 [<xref ref-type="bibr" rid="hanspub.44431-ref45">45</xref>] 应用免疫组化法分析研究乳腺癌患者病理组织中LAG-3的蛋白表达与临床病理的关系，结果发现LAG-3+的乳腺癌患者预后不良。Feng等 [<xref ref-type="bibr" rid="hanspub.44431-ref46">46</xref>] 研究发现，LAG-3在NK/T 型淋巴瘤中高表达，其阳性表达的淋巴瘤生存期短。目前多项关于抗LAG-3抗体治疗恶性肿瘤的研究正处于临床试验阶段，通过阻断LAG-3的表达，增强T细胞免疫应答，进而达到抗肿瘤目的。</p></sec><sec id="s8_4"><title>4.4. VISTA</title><p>近年来，在抗PD-1或抗CTLA-4的肿瘤免疫治疗，出现获得性抵抗的机制中，研究发现VISTA可能代表另一个补偿性的抑制性通路。VISTA免疫检查点已逐渐成为肿瘤免疫抑制剂治疗研究的热点，VISTA (V-domain Ig suppressor of T cell activation)是一个新发现的共抑制分子，也被称为PD-1H (Programmed death-1 homolog)，属于Ig超家族的成员之一。VISTA广泛表达于造血细胞表面，在抗原呈递细胞(APCs)及T细胞表面也有表达，且VISTA无论表达在APCs上还是T细胞上，均表现出对T细胞应答的抑制作用 [<xref ref-type="bibr" rid="hanspub.44431-ref47">47</xref>]。VISTA的表达在经过伊匹木单抗治疗后的前列腺癌患者体内增高。这些结果表明，VISTA可能代表另一个补偿性的抑制性通路，在肿瘤的抗PD-1/CTLA-4治疗出现获得性免疫抵抗时，结合VISTA和VISTA/CTLA-4联合阻滞可能是癌症治疗的一个有前途的新选择。</p></sec></sec><sec id="s9"><title>5. 结语</title><p>宫颈癌是女性生殖系统常见的恶性肿瘤，对于年轻有生育要求以及局部晚期宫颈癌患者，传统的手术加放疗的治疗手段并未取得令人满意的疗效，因而宫颈癌的靶向治疗成为目前研究的热点。分子靶向药物虽然给妇科恶性肿瘤的治疗带来了新的希望，但大多数肿瘤分子靶向治疗的临床试验结果都远非所期待的那样令人满意，肿瘤免疫逃逸一直是治疗难题，但近年来研究发现免疫检查点阻断药物能阻断肿瘤细胞对免疫系统的负向调节作用，增强免疫系统对肿瘤细胞监视攻击的能力，阻断PD-1、CTLA4信号途径的药物已进入临床，并取得良好疗效，但也存在着诸如脱靶效应、个体疗效差异等问题，研发更多的免疫检查点阻断药物迫在眉睫。</p></sec><sec id="s10"><title>文章引用</title><p>李玉英,赵 丽,袁 芳. 新型免疫检查点在宫颈癌中的应用前景Application Prospects for New Immune Checkpoints in Cervical Cancer[J]. 临床医学进展, 2021, 11(08): 3418-3425. https://doi.org/10.12677/ACM.2021.118496</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44431-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">WHO (2021) Global Health Estimates 2020: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2019[Z/OL].  
&lt;br&gt;https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death, 2021-02-20.</mixed-citation></ref><ref id="hanspub.44431-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">王宇, 宋淑芳, 刘凤. 我国宫颈癌流行病学特征和发病高危因素的研究进展[J]. 中国妇幼保健, 2019, 34(5): 1206-1208.</mixed-citation></ref><ref id="hanspub.44431-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Arora, E., Masab, M., Mittar, P., et al. (2018) Role of Immune Checkpoint Inhibitors in Advanced or Recurrent Endometrial Cancer. Cureus, 10, e2521. &lt;br&gt;https://doi.org/10.7759/cureus.2521</mixed-citation></ref><ref id="hanspub.44431-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Linhares, A.D., Leitner, J., Grabmeier-Pfistershammer, K., et al. (2018) Not Alloimmune Checkpoints Are Created Equal. Frontiers in Immunology, 9, 1909. &lt;br&gt;https://doi.org/10.3389/fimmu.2018.01909</mixed-citation></ref><ref id="hanspub.44431-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Chen, D.S. and Mellman, I. (2013) Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity, 39, 1-10.  
&lt;br&gt;https://doi.org/10.1016/j.immuni.2013.07.012</mixed-citation></ref><ref id="hanspub.44431-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Beatty, G.L. and Gladney, W.L. (2015) Immune Escape Mechanisms as a Guide for Cancer Immunotherapy. Clinical Cancer Research, 21, 687-692. &lt;br&gt;https://doi.org/10.1158/1078-0432.CCR-14-1860</mixed-citation></ref><ref id="hanspub.44431-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Zou, W. (2005) Immunosuppressive Networks in the Tumour Environment and Their Therapeutic Relevance. Nature Reviews Cancer, 5, 263-274. &lt;br&gt;https://doi.org/10.1038/nrc1586</mixed-citation></ref><ref id="hanspub.44431-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Topalian, S.L., Drake, C.G. and Pardoll, D.M. (2015) Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell, 27, 450-461. &lt;br&gt;https://doi.org/10.1016/j.ccell.2015.03.001</mixed-citation></ref><ref id="hanspub.44431-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Grupp, S.A., Kalos, M., Barrett, D., et al. (2013) Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia. The New England Journal of Medicine, 368, 1509-1518. &lt;br&gt;https://doi.org/10.1056/NEJMoa1215134</mixed-citation></ref><ref id="hanspub.44431-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Son, J.Y., Park, S.Y., Kim, S.J., et al. (2014) EW-7197, a Novel ALK-5 Kinase Inhibitor, Potently Inhibits Breast to Lung Metastasis. Molecular Cancer Therapeutics, 13, 1704-1716. &lt;br&gt;https://doi.org/10.1158/1535-7163.MCT-13-0903</mixed-citation></ref><ref id="hanspub.44431-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Couzin-Frankel, J. (2013) Breakthrough of the Year 2013. Cancer Immunotherapy. Science, 342, 1432-1433.  
&lt;br&gt;https://doi.org/10.1126/science.342.6165.1432</mixed-citation></ref><ref id="hanspub.44431-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Heymach, J., Krilov, L., Alberg, A., et al. (2018) Clinical Cancer Advances 2018: Annual Report on Progress against Cancer from the American Society of Clinical Oncology. Journal of Clinical Oncology, 36, 1020-1044.  
&lt;br&gt;https://doi.org/10.1200/JCO.2017.77.0446</mixed-citation></ref><ref id="hanspub.44431-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Sanmamed, M.F. and Chen, L. (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell, 175, 313-326. &lt;br&gt;https://doi.org/10.1016/j.cell.2018.09.035</mixed-citation></ref><ref id="hanspub.44431-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of Cancer: The Next Generation. Cell, 144, 646-674.  
&lt;br&gt;https://doi.org/10.1016/j.cell.2011.02.013</mixed-citation></ref><ref id="hanspub.44431-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Creelan, B.C. (2014) Update on Immune Checkpoint Inhibitors in Lung Cancer. Cancer Control, 21, 80-89.  
&lt;br&gt;https://doi.org/10.1177/107327481402100112</mixed-citation></ref><ref id="hanspub.44431-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Dunn, G.P., Old, L.J. and Schreiber, R.D. (2004) The Three ES of Cancer Immunoediting. Annual Review of Immunology, 22, 329-360. &lt;br&gt;https://doi.org/10.1146/annurev.immunol.22.012703.104803</mixed-citation></ref><ref id="hanspub.44431-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Vesely, M.D., Kershaw, M.H., Schreiber, R.D., et al. (2011) Natural Innate and Adaptive Immunity to Cancer. Annual Review of Immunology, 29, 235-271. &lt;br&gt;https://doi.org/10.1146/annurev-immunol-031210-101324</mixed-citation></ref><ref id="hanspub.44431-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Gong, J., Chehrazi-Raffle, A., Reddi, S., et al. (2018) Development of PD-1 and PD-L1 Inhibitors as a Form of Cancer Immunotherapy: A Comprehensive Review of Registration Trials and Future Considerations. Journal for Immuno Therapy of Cancer, 6, 8. &lt;br&gt;https://doi.org/10.1186/s40425-018-0316-z</mixed-citation></ref><ref id="hanspub.44431-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Barquin-Garcia, A., Molina-Cerrillo, J., Garrido, P., et al. (2019) New Oncologic Emergencies: What Is There to Know about Inmunotherapy and Its Potential Side Effects? European Journal of Internal Medicine, 66, 1-8.</mixed-citation></ref><ref id="hanspub.44431-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Fajardo, C.A., Guedan, S., Rojas, L.A., et al. (2017) Oncolytic Adenoviral Delivery of an EGFR-Targeting T Cell Engager Improves Antitumor Efficacy. Cancer Research, 77, 2052-2063.  
&lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-16-1708</mixed-citation></ref><ref id="hanspub.44431-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Monney, L., Sabatos, C.A., Gaglia, J.L., et al. (2002) Th1-Specific Cell Surface Protein Tim-3 Regulates Macrophage Activation and Severity of an Autoimmune Disease. Nature, 415, 536-541. &lt;br&gt;https://doi.org/10.1038/415536a</mixed-citation></ref><ref id="hanspub.44431-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Parra, E.R., Villalobos, P., Zhang, J., et al. (2018) Immunohistochemical and Image Analysis-Based Study Demonstrate That Several Immune Checkpoints Are Co-Expressed in Non-Small Cell Lung Carcinoma Tumors. Journal of Thoracic Oncology, 13, 779-791. &lt;br&gt;https://doi.org/10.1016/j.jtho.2018.03.002</mixed-citation></ref><ref id="hanspub.44431-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Wu, J., Lin, G., Zhu, Y., et al. (2017) Low TIM3 Expression Indicates Poor Prognosis of Metastatic Prostate Cancer and Acts as an Independent Predictor of Castration Resistant Status. Scientific Reports, 7, Article No. 8869.  
&lt;br&gt;https://doi.org/10.1038/s41598-017-09484-8</mixed-citation></ref><ref id="hanspub.44431-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, G., Sprengers, D., Boor, P.P.C., et al. (2017) Antibodies against Immune Checkpoint Molecules Restore Functions of Tumor Infiltrating T Cells in Hepatocellular Carcinomas. Gastroenterology, 153, 1107.  
&lt;br&gt;https://doi.org/10.1053/j.gastro.2017.06.017</mixed-citation></ref><ref id="hanspub.44431-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Karabon, L., Partyka, A., Jasek, M., et al. (2016) Intragenic Variations in BTLA Gene Influence mRNA Expression of BTLA Gene in Chronic Lymphocytic Leukemia Patients and Confer Susceptibility to Chronic Lymphocytic Leukemia. Archivum Immunologiae et Therapiae Experimentalis, 64, 137-145. &lt;br&gt;https://doi.org/10.1007/s00005-016-0430-x</mixed-citation></ref><ref id="hanspub.44431-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Mcintire, J.J., Umetsu, S.E., Akbari, O., et al. (2001) Identification of Tapr (an Airway Hyperreactivity Regulatory Locus) and the Linked Tim Gene Family. Nature Immunology, 2, 1109-1116. &lt;br&gt;https://doi.org/10.1038/ni739</mixed-citation></ref><ref id="hanspub.44431-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">陶景莲, 李丽娟, 邵宗鸿. TIM3在肿瘤微环境中作用的研究进展[J]. 中国免疫学杂志, 2016, 32(7): 1070-1073.  
&lt;br&gt;https://doi.org/10.3969/j.issn.1000-484X.2016.07.032</mixed-citation></ref><ref id="hanspub.44431-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Friedlaender, A., Addeo, A. and Banna, G. (2019) New Emerging Targets in Cancer Immunotherapy: The Role of TIM3. ESMO Open, 4, e000497. &lt;br&gt;https://doi.org/10.1136/esmoopen-2019-000497</mixed-citation></ref><ref id="hanspub.44431-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Jacob, C., et al. (2020) Looking Past PD-L1: Expression of Immune Checkpoint TIM-3 and Its Ligand Galectin-9 in Cervical and Vulvar Squamous Neoplasia. Modern Pathology, 33, 1182-1192.  
&lt;br&gt;https://doi.org/10.1038/s41379-019-0433-3</mixed-citation></ref><ref id="hanspub.44431-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Das, M., Zhu, C. and Kuchroo, V.K. (2017) Tim-3 and Its Role in Regulating Anti-Tumor Immunity. Immunological Reviews, 276, 97-111. &lt;br&gt;https://doi.org/10.1111/imr.12520</mixed-citation></ref><ref id="hanspub.44431-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Boles, K.S., Vermi, W., Facchetti, F., et al. (2009) A Novel Molecular Interaction for the Adhesion of Follicular CD4 T Cells to Follicular DC. European Journal of Immunology, 39, 695-703. &lt;br&gt;https://doi.org/10.1002/eji.200839116</mixed-citation></ref><ref id="hanspub.44431-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Lozano, E., Dominguez-Villar, M., Kuchroo, V., et al. (2012) The TIGIT/CD226 Axis Regulates Human T Cell Function. The Journal of Immunology, 188, 3869-3875. &lt;br&gt;https://doi.org/10.4049/jimmunol.1103627</mixed-citation></ref><ref id="hanspub.44431-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Johnston, R.J., Comps-Agrar, L., Hackney, J., et al. (2014) The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8(+) T Cell Effector Function. Cancer Cell, 26, 923-937. &lt;br&gt;https://doi.org/10.1016/j.ccell.2014.10.018</mixed-citation></ref><ref id="hanspub.44431-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Stanietsky, N., Simic, H., Arapovic, J., et al. (2009) The Interaction of TIGIT with PVR and PVRL2 Inhibits Human NK Cell Cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 106, 17858-17863. &lt;br&gt;https://doi.org/10.1073/pnas.0903474106</mixed-citation></ref><ref id="hanspub.44431-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Minu, K., Srivastava, R.Y., Erin, M., et al. (2017) Abstract 2612: Anti-TIGIT Induces T Cell Mediated Anti-Tumor Immune Response and Combines with Immune Checkpoint Inhibitors to Enhance Strong and Long Term Anti-Tumor Immunity. Cancer Research, 77, 2612-2612. &lt;br&gt;https://doi.org/10.1158/1538-7445.AM2017-2612</mixed-citation></ref><ref id="hanspub.44431-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Park, A.I., Srivastava, M., Mayes, E., et al. (2017) Abstract 2003: Antibody against TIGIT (T Cell Immunoreceptor with Ig and ITIM Domains) Induces Anti-Tumor Immune Response and Generates Long-Term Immune Memory. Cancer Research, 77, 2003. &lt;br&gt;https://doi.org/10.1158/1538-7445.AM2017-2003</mixed-citation></ref><ref id="hanspub.44431-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Blessin, N.C., Simon, R., Kluth, M., et al. (2019) Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer. Annals of Surgical Oncology, 2019, Article ID: 5160565.</mixed-citation></ref><ref id="hanspub.44431-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Triebel, F., Jitsukawa, S., Baixeras, E., et al. (1990) LAG-3, a Novel Lymphocyte Activation Gene Closely Related to CD4. Journal of Experimental Medicine, 171, 1393-1405. &lt;br&gt;https://doi.org/10.1084/jem.171.5.1393</mixed-citation></ref><ref id="hanspub.44431-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Anderson, A.C., Joller, N. and Kuchroo, V.K. (2016) Lag-3, TIM-3, and TIGIT: Co-Inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity, 44, 989-1004. &lt;br&gt;https://doi.org/10.1016/j.immuni.2016.05.001</mixed-citation></ref><ref id="hanspub.44431-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Joller, N. and Kuchroo, V.K. (2017) Tim-3, Lag-3, and TIGIT. Current Topics in Microbiology and Immunology, 410, 127-156. &lt;br&gt;https://doi.org/10.1007/82_2017_62</mixed-citation></ref><ref id="hanspub.44431-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Dijkstra, J.M., Somamoto, T., Moore, L., et al. (2006) Identification and Characterization of a Second CD4-Like Gene in Teleost Fish. Molecular Immunology, 43, 410-419. &lt;br&gt;https://doi.org/10.1016/j.molimm.2005.03.005</mixed-citation></ref><ref id="hanspub.44431-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Di Carlo, E., Cappello, P., Sorrentino, C., et al. (2005) Immunological Mechanisms Elicited at the Tumour Site by Lymphocyte Activation Gene-3 (LAG-3) versus IL-12: Sharing a Common Th1 Anti-Tumour Immune Pathway. The Journal of Pathology, 205, 82-91. &lt;br&gt;https://doi.org/10.1002/path.1679</mixed-citation></ref><ref id="hanspub.44431-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Gros, A., Robbins, P.F., Yao, X., et al. (2014) PD-1 Identifies the Patient-Specific CD8(+) Tumor-Reactive Repertoire Infiltrating Human Tumors. Journal of Clinical Investigation, 124, 2246-2259. &lt;br&gt;https://doi.org/10.1172/JCI73639</mixed-citation></ref><ref id="hanspub.44431-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">He, Y., Rivard, C.J., Rozeboom, L., et al. (2016) Lymphocyte-Activation Gene-3, an Important Immune Checkpoint in Cancer. Cancer Science, 107, 1193-1197. &lt;br&gt;https://doi.org/10.1111/cas.12986</mixed-citation></ref><ref id="hanspub.44431-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Burugu, S., Gao, D., Leung, S., et al. (2017) LAG-3+ Tumor Infiltrating Lymphocytesin Breast Cancer: Clinical Correlates and Association with PD-1/PD-L1+ Tumors. Annals of Oncology, 28, 2977-2984.  
&lt;br&gt;https://doi.org/10.1093/annonc/mdx557</mixed-citation></ref><ref id="hanspub.44431-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Feng, Y., Zhong, M., Liu, Y., et al. (2018) Expression of TIM-3 and LAG-3 in Extranodal NK/T Cell Lymphoma, Nasal Type. Histology and Histopathology, 33, 307-315.</mixed-citation></ref><ref id="hanspub.44431-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, M., et al. (2018) VISTA Expression Associated with CD8 Confers a Favorable Immune Microenvironment and Better Overall Survival in Hepatocellular Carcinoma. BMC Cancer, 18, Article No. 511.  
&lt;br&gt;https://doi.org/10.1186/s12885-018-4435-1</mixed-citation></ref></ref-list></back></article>